USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Vesalius Cardiovascular Inc.

USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company

The verdict

According to USPTO PatentsView, Vesalius ranks #43,936 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 5 technology areas.

#43,936
of 49,997 US assignees by volume
Top 25%
by Innovation Score (44.8/100)
17.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R43936 · Foreign Corporation #43,936 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 6 grants
  • LOWER-Q #43,936/49,997
  • PHOTO-FINISH Verent
  • CPC-NARROW A61F · 5 areas
  • INNOV-PAR 44.8/100
  • CLAIMS-RICH 17.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2020–2025 · 6y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Verent LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Vesalius

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Vesalius's Innovation Score is 44.8/100 (top 25% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Vesalius's grants concentrate

Vesalius Cardiovascular Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2024 (2 grants) versus a trough of 1 in 2020. By volume, Vesalius sits between Verent LLC and Viasystems Technologies Corp. L.L.C..

Vesalius's three-year grant acceleration

Vesalius Cardiovascular Inc. shows 4 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Vesalius's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Vesalius holds 6 patents at rank #43,875, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Vesalius

By rank, the assignees closest to #43,875 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Vesalius's primary technology class.

Vesalius's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 25% higher than 75% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 20202022202320242025 1
USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Vesalius Cardiovascular Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 1 16.7%
2022 1 16.7%
2023 1 16.7%
2024 2 33.3%
2025partial year 1 16.7%

Where it ranks

Overall rank by patents

#43,936

of 49,997 tracked assignees

Innovation Score

44.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Vesalius Cardiovascular Inc.'s patent record in context - here's where to go next.

  • Vesalius Cardiovascular Inc.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 100% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #43,936 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Vesalius Cardiovascular Inc. against Verent LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 44.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.